Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity

REHOVOT, Israel, June 2, 2026 /PRNewswire/ -- Evogene Ltd. ("Evogene") (NASDAQ:EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, today announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, Biomica Ltd., in combination with Nivolumab in patients with advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC).